


COVID-19 vs Wellisair WADU-02

To understand **Wellisair's** efficacy against the pandemic **COVID-19** Coronavirus (initially 2019-nCoV) that emerged in 2019 in Wuhan, one must understand the morphological structure of this type of virus, as well as its family classification.

Coronaviruses are in the Coronavirinae subfamily of the Coronaviridae family, in the order Nidovirales. They are divided into 4 VOC subgenres: Alpha, Beta, Delta and Gamma. **COVID-19** corresponds to the **SARS** family, classified as Betacoronavirus of lineage "B", originating in bats.




**NEW
2020**



COVID-19 vs Wellisair WADU-02

Due to the short time of the appearance of this strain, direct tests of the **Wellisair** technology against the virus have not been possible, however the device has already been installed at **South Korea's Medical Centre for COVID-19**.



Luckily, it has been possible to test a virus with a morphological structure similar to the coronavirus, such as the **Respiratory Syncytial Virus (RSV)**.

RSV is classified within Pneumoviruses, specifically in the Paramyxoviridae family, and even though it is not within the same family, this virus shares great similarities to **COVID-19** as lipid membrane and glycoprotein projections.

Based on the results obtained with **Wellisair** in viruses with similar structures (**RSV**) to the **COVID-19** Coronavirus, we can expect that: the efficacy of our new technology will have an expected elimination result of an average of 92 to 99% depending on the relative indoor conditions.

